

## CORRIGENDUM

# CORRIGENDUM: Commentary on Pharmacometrics for Immunotherapy

MJ Garrido, P Berraondo and IF Trocóniz

*CPT Pharmacometrics Syst. Pharmacol.* (2017) 6, 8–10; doi:10.1002/psp4.12162; published online 20 December 2016.

The authors note an error in the second paragraph of the BACKGROUND section. The paragraph should read as set below. Corrected text is set in bold type.

The current issue of *CPT: Pharmacometrics & Systems Pharmacology* focuses on the application of population pharmacokinetic/pharmacodynamics analysis (popPKPD) to the clinical development of two new immune-modulatory agents acting as antagonists of the PD-1 cell surface receptor, pembrolizumab (**Merck Sharp and Dohme, NJ, USA**) and nivolumab (Bristol-Myers Squibb, Princeton, NJ).

The authors regret this error.